Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omarigliptin add-on to glimepiride and metformin in T2DM
NCT01704261Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2012
- Primary completion
- Dec 2014
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of omarigliptin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started Oct 2012; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01704261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01704261.